An update from Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) is now available.
Shanghai Haohai Biological Technology Co., Ltd. announced its preliminary annual results for 2024, revealing a slight increase in revenue by 1.64% to RMB 269,765.79 million. Despite a decrease in operating profit and profit before tax, the company reported a marginal rise in net profit attributable to shareholders. The company experienced a significant increase in share capital by 35.99% due to the conversion of capital reserve into share capital. These results reflect the company’s stable financial performance, with a slight improvement in basic earnings per share and return on net assets.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a company in the biotechnology sector, primarily focused on developing biological products and technologies. The company operates within the healthcare industry, offering products and services that cater to medical and health-related needs.
YTD Price Performance: -1.88%
Average Trading Volume: 179,480
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: HK$13.23B
For an in-depth examination of 6826 stock, go to TipRanks’ Stock Analysis page.